Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HRAS
REST API REST API
Homo sapiens
HRAS is differentially expressed in 264 experiments: 109 organism parts: bone marrow, amygdala, ... (107 more);, 171 disease states: normal, Huntington's disease, ... (169 more);, 65 cell types 302 cell lines 31 compound treatments and 73 other conditions.
Synonyms HRAS1
Orthologs hrasb (Danio rerio)   RAS2 (Saccharomyces cerevisiae)   Hras1 (Mus musculus)   RASH_CHICK (Gallus gallus)   RAS1 (Saccharomyces cerevisiae)   Ras85D (Drosophila melanogaster)   RASH_RAT (Rattus norvegicus)   hras (Xenopus laevis)   HRAS (Bos taurus)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, GTPase activity, protein binding, apoptosis, visual learning, cytoplasm, cell proliferation, epidermal growth factor receptor signaling pathway, intracellular, negative regulation of cell proliferation, positive regulation of cell proliferation, membrane, Golgi membrane, Golgi apparatus, social behavior, MAPKKK cascade, cell cycle arrest, insulin receptor signaling pathway, blood coagulation, membrane fraction, GTP catabolic process, soluble fraction, GTP binding, activation of MAPKK activity, actin cytoskeleton organization, induction of apoptosis, Ras protein signal transduction, axon guidance, small GTPase mediated signal transduction, synaptic transmission, microsome, cell surface receptor linked signaling pathway, nucleus, positive regulation of DNA replication, nucleotide binding, chemotaxis, perinuclear region of cytoplasm, integral to membrane, protein C-terminus binding, signal transduction, organ morphogenesis, protein transport, positive regulation of Ras protein signal transduction, negative regulation of neuron apoptosis, endocytosis, striated muscle cell differentiation, cell aging, regulation of long-term neuronal synaptic plasticity, leukocyte migration, positive regulation of ERK1 and ERK2 cascade, induction of apoptosis by intracellular signals, positive regulation of Rac protein signal transduction, positive regulation of epithelial cell proliferation, ferrous iron transmembrane transporter activity, regulation of synaptic transmission, GABAergic, nerve growth factor receptor signaling pathway, ferrous iron transport, Ral guanyl-nucleotide exchange factor activity, positive regulation of MAPKKK cascade, mitotic cell cycle G1/S transition checkpoint, cellular senescence
InterPro Term MIRO-like, ProtSyn_GTP-bd, Small_GTPase, Small_GTP-bd_dom, Fe2_transport_prot_B_N, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession Q9UM97, Q71SP6, P01112, P78460, E5FF39
Gene-Disease Assocation THYROID CARCINOMA, HURTHLE CELL, BLADDER CANCER, COSTELLO SYNDROME, THYROID CARCINOMA, FOLLICULAR; FTC
Search EB-eye ENSG00000174775
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-2549, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
HCC1143
2
E-MTAB-62, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
BT474
2
E-MEXP-440, E-MTAB-62
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
ITM-ST
1
E-GEOD-2487
296 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
hematopoietic progenitor cells
1
E-MEXP-70
type I helper T cell
1
E-GEOD-3982
721 B lymphoblast
1
1
E-AFMX-5
ciliary muscle
1
E-GEOD-492
59 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2508, E-GEOD-15960, E-MEXP-2069, E-GEOD-22148, ... (42 experiments)

Factor Value U/D Experiments
prostate cancer
2
E-GEOD-6919, E-MTAB-62
astrocytoma
2
E-GEOD-4290, E-MTAB-62
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
Huntington's disease
1
2
E-AFMX-6, E-GEOD-3790, E-GEOD-1751
gulf war illness
1
E-MEXP-2069
165 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (19 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5824, E-GEOD-20719, E-MEXP-1601, E-GEOD-412, E-TABM-782, ... (6 experiments)
unknown
1
E-GEOD-7307
lipopolysaccharide
1
E-GEOD-3720
mercury dichloride
1
E-GEOD-6907
5-fluorouridine
1
E-GEOD-995
vanadium pentoxide
1
E-GEOD-5339
25 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254

Initial distant metastases
studied in E-GEOD-22541

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-MEXP-70

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.442 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM